Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 3/20 | 0.36 |
| ▸ | PRKACG | P22612 | 3/20 | 0.36 |
| ▸ | PRKACB | P22694 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914997 | 0.88 | CYP11B2 (0.48) | CYP11B2HDAC1SCN9ACYP11B1CNR2 | |
| SCHEMBL2656820 | 0.82 | CYP11B2 (0.51) | CYP11B2SCN9ACYP11B1CNR2ALDH1A1 | |
| SCHEMBL2659090 | 0.79 | CYP11B2 (0.39) | CYP11B2HDAC1SCN9ACYP11B1CNR2 | |
| SCHEMBL2656404 | 0.79 | CYP11B2 (0.39) | CYP11B2HDAC1SCN9ACYP11B1CNR2 | |
| SCHEMBL2658369 | 0.79 | CYP11B2 (0.39) | CYP11B2HDAC1SCN9ACYP11B1PLAUR | |
| SCHEMBL2668182 | 0.79 | CYP11B2 (0.39) | CYP11B2HDAC1SCN9ACYP11B1CNR2 | |
| SCHEMBL2657440 | 0.76 | BRD4 (0.40) | CYP11B2SCN9AALDH1A1ADORA2AKDM4E | |
| SCHEMBL10061101 | 0.74 | SLC22A12 (0.48) | CYP11B2SCN9ACNR2 | |
| SCHEMBL14141241 | 0.74 | PLAUR (0.47) | PLAURALDH1A1NPSR1TDP1KDM4E | |
| SCHEMBL5072719 | 0.73 | TDP1 (0.48) | CYP11B2CYP11B1ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2157859-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | Takeda Pharmaceutical Company Limited (JP) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | GCKR, GCK, KHK | CYP11B2 2151/4885HDAC1 238/4885SCN9A 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.